News
RVMD
161.20
+1.11%
1.77
Does First Line Pancreatic Data Change The Bull Case For Revolution Medicines (RVMD)?
Simply Wall St · 56m ago
Revolution Medicines Drugged a Target Scientists Called “Undruggable” for Decades. Buy the Stock Hand Over Fist?
The Motley Fool · 3h ago
Midday Fly By: Anthropic drops in day two, Gap reports Q3 earnings beat
TipRanks · 7h ago
Erasca: 'Buy' On Expanded KRAS Targeting ERAS-4001 And Bristol-Myers Squibb Collaboration Tie-Up
Seeking Alpha · 8h ago
Revolution Medicines Highlights Strong 12-Month Overall Survival Rate for Lead Cancer Drug Regimen
Benzinga · 9h ago
Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Revolution Medicines (RVMD) and Evaxion Biotech (EVAX)
TipRanks · 12h ago
Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303
Benzinga · 18h ago
Revolution Medicines presents updated Phase 1/2 data for RASONQUE
TipRanks · 1d ago
Erasca: ERAS-0015 In High Demand, Phase 1 Update On Tap
Seeking Alpha · 1d ago
Leerink bullish on Erasca, initiates with an Outperform
TipRanks · 3d ago
Revolution Medicines Price Target Maintained With a $350.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $350 Price Target
Benzinga · 3d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 3d ago
EC Approves Revolution's RASONQUE For Pancreatic Ductal Adenocarcinoma In All EU Member States
NASDAQ · 4d ago
Revolution Medicines says EC approves Rasonque in metastatic pancreatic cancer
TipRanks · 4d ago
Weekly Report: what happened at RVMD last week (1109-1113)?
Weekly Report · 4d ago
Revolution Medicines Price Target Cut to $247.00/Share From $272.00 by Morgan Stanley
Dow Jones · 11/13 18:15
Revolution Medicines Is Maintained at Overweight by Morgan Stanley
Dow Jones · 11/13 18:15
Morgan Stanley Maintains Overweight on Revolution Medicines, Lowers Price Target to $247
Benzinga · 11/13 18:05
Revolution Medicines price target lowered to $247 from $272 at Morgan Stanley
TipRanks · 11/13 11:30
More
Webull provides a variety of real-time RVMD stock news. You can receive the latest news about Revolution Medicines, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RVMD
Revolution Medicines, Inc. is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The Company is advancing a pipeline of RAS(ON) Inhibitors, daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor are in clinical development. The Company's pipeline also focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). The Daraxonrasib, our RAS(ON) multi-selective inhibitor, is designed as an oral, tri-complex inhibitor of multiple RAS(ON) variants containing cancer driver mutations at all three of the major RAS mutation hotspot positions, G12, G13, and Q61.